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Abstract
Background:  The aim of this study was to investigate the analgesic effects of intravenous
flurbiprofen axetil for the refractory pain in cancer patients.
Methods: 2109 patients were screened from the department of medical oncology, the first
affiliated hospital of Anhui medical university in China between October of 2007 and October of
2008. Thirty-seven cases of cancer patients who had bad effect from anaesthetic drugs were
received administration of intravenous flurbiprofen axetil with dose of 50 mg/5 ml/day. The pain
score was evaluated for pre- and post- treatment by Pain Faces Scale criteria, and the side effects
were also observed.
Results: Intravenous flurbiprofen axetil increased the analgesic effects. The total effective rate was
92%. The side effects, such as abdominal pain, alimentary tract bleeding which were found in using
NSAIDs or constipation, nausea, vomit, sleepiness which were found in using opioid drugs did not
be found.
Conclusion: Intravenous flurbiprofen axetil could provide better analgesia effects and few side
effects to patients with refractory cancer pain. It could also increase analgesia effects when
combining with anesthetic drugs in treatment of moderate or severe pain, especially breakthrough
pain, and suit to patients who can not take oral drugs for the reason of constipation and
psychosomatic symptoms.
Background
Pain is a common problem in cancer patient. About one-
third of patients being treated for cancer have pain. More
than two-thirds of patients with advanced cancer have
pain [1]. Controlling pain and managing symptoms are
important goals of cancer treatment [2].
Flurbiprofen is a non-selective cyclooxygenase inhibitor
used in clinic as nonsteroidal anti-inflammatory drug [3].
Flurbiprofen axetil, an injectable prodrug of flurbiprofen
[4], has been reported to be associated with a reduction
postoperative pain [5,6], propofol injection pain [7,8],
and in initial treated pain induced from cancer [9]. The
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role of flurbiprofen axetil are not yet clear in the routinely
administration of refractory cancer pain. In the present
study, we reported the role of intravenous flurbiprofen
axetil in this area.
Methods
Patients
Cancer pain cases whose pain had not been treated satis-
factorily with routine narcotics were selected from the
department of medical oncology, the first affiliated hospi-
tal of Anhui medical university in China between October
of 2007 and October of 2008. Each cancer case was diag-
nosed and confirmed by histopathology or cytopathol-
ogy. Clinical data and follow-up information were
obtained from the hospital records. The study protocol
was approved by the local institutional ethics committee,
and verbal informed consent was obtained from each
patient. Patients with difficulty communicating, a history
of adverse response to flubiprofen axetil, or who felt no
pain after received other analgesic drugs within 24 hours
were excluded.
Dosage and usage of flurbiprofen axetil injection
All selected patients were received 50 mg/5 ml/day of
intravenous flurbiprofen axetil injection (50 mg/5 ml,
Beijing Tide Pharmaceutical. Co., Ltd, Beijing, China), as
flurbiprofen axetil 50 mg added in 100 ml of 0.9% isot-
onic saline every time through vein within 30 minutes.
Dosage and usage of the anaesthetic drugs such as Oxyco-
done, Tramadol, Duragesic and adjuvant drugs such as
diazepam, carbamazepine which being used initially were
not changed, or be reduced and ceased after the pain was
relieved completely. Other accompanying adjuvant treat-
ments also had been included chemotherapy, radiother-
apy, best sustain therapy, bisphosphonate therapy, and
etc.
Evaluating criteria
We evaluated cancer pain intensity by Pain Faces Scale cri-
teria [10], and the three grades as: Mild pain (1–3): Cancer
pain could be endurable, and sleep was effected slightly,
action was freely, no pain was in the patient's face; Mod-
erate pain (4–6): Cancer pain could be endurable yet, and
sleep was effected obviously, action was limited, pain was
showed in the patient's face; Severe pain (7–10): Cancer
pain could not be endurable, and sleep was effected
severely, action was limited hardly, more pain was
showed in the patient's face, body's style was passively.
Pain relief was recorded based on four-scale criteria [11]:
Complete relief (CR): The pain was disappeared com-
pletely, or alleviated significantly, no anesthetic drug must
be used; Partial relief (PR): The pain was alleviated signif-
icantly than before. The sleep was not disturbed by and
large. Patient could live in normal or use a few anesthetic
drugs; Minimal relief (MR): The pain was alleviated than
before, but it still felt obviously. The sleep was still dis-
turbed by the pain, and the dosage of anesthetic drugs was
not reduced significantly than before; No effect (NR): The
pain was not alleviated significantly than before, or the
dosage of anesthetic drugs were not reduced than before.
CR and PR were regarded as effective response to cancer
pain treatment.
Side effects
Side effects were observed and classified according to the
WHO acute and sub-acute toxicity classifying criteria of
anticancer drugs [12]. Some symptoms such as swirl, nau-
sea, vomit, abdominal pain, diarrhea, astriction, dysuria,
vessel stimulate, etc, were noticed especially after flurbi-
profen axetil had being used.
Results
A total of 2109 patients were screened. 37 patients were
enrolled based on the criteria (22 men, 15 women; mean
[SD] age, 57[13] years, mean [SD] height, 161[9] cm;
mean [SD] body weight, 56[11] kg). Other clinic charac-
teristics of those patients were showed in Table 1.
Thirty-three cases of refractory cancer pain were received
50 mg of intravenous flurbiprofen axetil injection every
day. Other four cases had to increase the dosage of flurbi-
profen axetil to 100 mg a day for the reason of insufficient
effect by 50 mg a day. Thirty-four patients were regarded
as partial relief or complete relief. The total effective rate
was 92%. The results of usage and analgesic effect were
showed in Table 2.
The side effect, gastrointestinal toxicity such as abdominal
pain, alimentary tract ulcers and bleeding which were
found in NSAIDs or constipation, nausea, vomit, sleepi-
ness and delirium which were found in opioid drugs did
not be found in all of the 37 cancer pain cases.
Discussion
In this study, we testified that intravenous flurbiprofen
axetil injection could increase the analgesic effects in
refractory cancer pain. Lipid microspheres (LM) were tar-
get-drug delivery carriers which could congregate selec-
tively in the site such as inflammation or injuring blood
vessel and change the distribution of drugs in vivo
[13,14]. Flurbiprofen axetil injection, 0.2 μm in diameter,
was composed of lipid microspheres and flurbiprofen
axetil[15]. It was target-congregated easily to tumor, espe-
cially malignant tumor for there had abundant fresh cap-
illary vessel and released inflammatory factor. The latter
could enlarge the fissure of endothelium cells and let it be
taken up by macrophages and neutrophils. So, the biosyn-
thesis of prostaglandin was restrained, and the analgesicJournal of Experimental & Clinical Cancer Research 2009, 28:33 http://www.jeccr.com/content/28/1/33
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effects of flurbiprofen axetil would be appeared [16]. Flur-
biprofen axetil injection always had better analgesic
effects in bone metastasis of tumor while nociceptor pain
was mainly expressed [9].
Anaesthetic anodynes were always used in moderate and
severe pain patients. It acted in central nerve system, and
the analgesic effects was not relative with the site or kind
of pain. But, side effects always happened, such as consti-
pation, breath inhibition, drug dependence, even exciting
central nerve system when it was used for long time [2].
Flurbiprofen axetil and other NSAIDs drugs acted in the
site of distal nerve. Its analgesic effects were always not
bad than anaesthetic anodynes when the inflammatory
medium was liberated in the site of muscle, tendon, liga-
ment, and bone. It could be used as first line anodyne and
combined with anaesthetic anodynes in corresponding
cancer pain [4]. Our results showed that intravenous flur-
biprofen axetil had better analgesic effect to cancer pain
with bone or vertebra metastasis. It could reduce the dos-
age of the anaesthetic drugs, or increase the analgesic
effects with little side effect, especially in patient who had
constipation or had a tendency of ileus. Our results
showed the analgesic effect was better than the Ou Yang's
report [9], and similar to the report by Xu et al [17]. Per-
haps for the reason of insufficient cases, we found that
flurbiprofen axetil had slight analgesic effect to cancer
pain in abdomen.
The half-life time of flurbiprofen axetil was 5.8 hours. Its
onset of action was about 15 minutes after being used,
and continued about 3 hours in post-operation. When it
was used in cancer patients, it began to work quickly
about in 30 minutes, and the duration of action was about
9 hours [18]. So it was especially suitable for break-
through pain to the patient who were using anaesthetic
anodyne. We found that most patients could obtain anal-
gesic effects after being added flurbiprofen axetil 50 mg
while their pain could not be controlled by anaesthetic
drugs. But in some patients, the analgesic effect was only
maintained 3–4 hours. So it need to be used continually
or time after time, or other analgetic administrations
should be used to the patients whose had severe cancer
pain but could not deal with mainline.
Sometimes oral NSAIDs drugs are restrictedly applied
mainly for the reason to stimulate patient's gastric
mucosa. Intravenous flurbiprofen axetil injection could
Table 1: Clinical characteristics of 37 patients with refractory 
cancer pain (number)
Cancer stage number
III stage 2
IV stage 35
Primary cancer
gastric (cardia) 5
oesophageal 1
rectal 1
lung 18
breast 3
prostate 3
the primary site not clear 6
Pain reason
bone metastasis 33 (including one incomplete ileus)
pleura invasion 2
ileus 2
Pain intensity
moderate 26
severe 11
Table 2: The usage and analgesic effect of flurbiprofen axetil in refractory cancer pain (number)
Using time (day)
Short 2
Long 34
average 12.5
mean 7
The initially anaesthetic drugs (number)
dosage and usage not changed 20
dosage decreased slightly 8
dosage decreased significantly 6
the initially drugs ceased 3
Combining with treatment (number)
chemotherapy 23
radiotherapy 2
best sustain therapy 6
bisphosphonate therapy 10
Pain relief (number)
complete relief 10 (9, bone metastasis; 1, pleura metastasis)
partial relief 24 (bone metastasis)
minimal relief 3 (2, abdominal pain in gastric cancer;
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avoid this side effect. In all of 1089 cases, the side effect
incidence rate was very low about 2.9% [18]. Most side
effects were in gastrointestinal tract such as nausea, vomit,
diarrhoea or in neuropsychosis such as fever, fear cold,
sleepiness, etc. Few cases expressed as subcutaneous
bleeding or pain in the injecting site. Perhaps our cases
were insufficient, no side effect of flurbiprofen axetil was
found in this study.
Conclusion
In general, cancer pain is considered as chronic. The pain
intensity ranges from mild to severe and present for a long
time. Harmless approach to therapy such as by oral or by
cutaneous are suggested by WHO. But, for some reasons
as constipation and psychosomatic symptoms, there has
many patients whose can not take drugs by oral, or can
not be used cutaneous anaesthetic drugs, intravenous flur-
biprofen axetil could exactly remedy the anaesthetic
drug's shortcoming, and let itself to be an important
switch drug.
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